Medical experts analyze and provide insights on safety findings from the Phase 3 ECHO trial, offering their professional interpretations of the data.
Odronextamab Earns European Approval in R/R Follicular Lymphoma, DLBCL
The European Commission’s decision represents the first regulatory approval of odronextamab for patients with follicular lymphoma or DLBCL.
Overcoming Physical and Social Barriers in the Lymphoma Field
Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.
FDA Approval Alert: Epcoritamab in Relapsed/Refractory Follicular Lymphoma
The approval of epcoritamab may impact treatment options in the R/R follicular lymphoma space, according to Tycel Phillips, MD.
Epcoritamab Approval Expands Bispecific Use in Follicular Lymphoma
Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.
EMA Validates Type II Application for Liso-cel in R/R Follicular Lymphoma
In Japan, liso-cel recently received approval for patients with previously treated relapsed/refractory follicular lymphoma.
Tafasitamab Combo Meets PFS End Point in R/R Follicular Lymphoma
Developers plan to submit a sBLA for tafasitamab in relapsed/refractory follicular lymphoma based on data from the inMIND trial.